Based on the CompuGroup Medical SE & Co. KGaA stock forecasts from 5 analysts, the average analyst target price for CompuGroup Medical SE & Co. KGaA is EUR 53.90 over the next 12 months. CompuGroup Medical SE & Co. KGaA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of CompuGroup Medical SE & Co. KGaA is Neutral, which is based on 7 positive signals and 7 negative signals. At the last closing, CompuGroup Medical SE & Co. KGaA’s stock price was EUR 47.32. CompuGroup Medical SE & Co. KGaA’s stock price has changed by +6.62% over the past week, +0.55% over the past month and -7.22% over the last year.
No recent analyst target price found for CompuGroup Medical SE & Co. KGaA
No recent average analyst rating found for CompuGroup Medical SE & Co. KGaA
Company Overview
CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for registered physicians, medical care centers, and physicians networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides administrative and billing-related software applications for pharmacies. Its software solution provides information and decision support to manage various aspects of supply chain for medication. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals, rehabilitation centers, social services, multi-location hospital networks and regional care organizations, and medical laboratories. The CHS segment provides IT security services, data-based product offers, software interface for sharing of information, clinical decision-making support, and medication and treatment databases for healthcare service providers, as well as digital healthcare stock, consumer portals, and mobile apps. This segment also offers security solutions for healthcare providers. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to CompuGroup Medical SE & Co. KGaA in June 2020. CompuGroup Medical SE & Co. KGaA was founded in 1987 and is headquartered in Koblenz, Germany. Address: Maria Trost 21, Koblenz, Germany, 56070 Read Less
CompuGroup Medical SE & Co. KGaA develops and sells software and information technology solutions for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and C...Read More
Stock Target Advisor's fundamental analysis for CompuGroup Medical SE & Co. KGaA's stock is Neutral.
COP:XETRA stock's dividend yield is 1.09%.
Our analysis grades COP:XETRA stock's dividend yield at F. This means that COP:XETRA stock's dividend yield
is above 50% of the stocks in the Health Information Services sector in the XETRA exchange.
Based on this COP:XETRA may be a average dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for COP:XETRA is EUR 53.90 over the next 12 months. The maximum analyst target price is EUR 68 while the minimum anlayst target price is EUR 36.5.
COP:XETRA stock's Price/Earning ratio is 34.32.
Our analysis grades COP:XETRA stock's Price / Earning ratio at D-. This means that COP:XETRA stock's Price/Earning ratio is above 40% of the stocks in the Health Information Services sector in the XETRA exchange.
Based on this COP:XETRA may be fairly valued for its sector
The last closing price of COP:XETRA's stock was EUR 47.32.
The most recent market capitalization for COP:XETRA is EUR 2.46B.
Based on targets from 5 analysts, the average taret price for COP:XETRA is projected at EUR 53.90 over the next 12 months.
This means that COP:XETRA's stock price may go up by +13.91% over the next 12 months.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for COP:XETRA !
Please login to proceed
Sorry - extended search is only available for registered users.
